US FDA declines to approve Summit lung cancer drug after trial misses key survival goal - Reuters

Reuters

US FDA declines to approve Summit lung cancer drug after trial misses key survival goal Reuters

US FDA declines to approve Summit lung cancer drug after trial misses key survival goal Reuters

Ver fuente original → ← Volver a noticias